Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) CMO, Todd Hobbs, M.D., will be presenting, “Rencofilstat (CRV431): Update on NASH Clinical Program,” on March 3 at the 6th Global NASH Congress in London. Dr. Hobbs will be...
The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...
Brookline Capital Partners analyst Kemp Dolliver assumed coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $4 price target. The stock finished at 73 cents on Jan. 31. Hepion’s rencofilstat is a...
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (MM). Rencofilstat exerted anti-cancer activity across a...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) research collaborator presented new findings from a preclinical study on the company’s lead drug candidate, rencofilstat, a potent inhibitor of cyclophilins, at the 2023 State of...
Hepion Pharmaceuticals (NASDAQ:HEPA) received $2.9-million in net proceeds from the sale of tax benefits under the company’s participation in the New Jersey Economic Development Authority (NJEDA) net operating loss...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract highlighting its lead drug candidate, rencofilstat, at the NASH-TAG 2023 Conference in Park City, Utah on Jan. 7. The presentation is entitled, “Rencofilstat...
Hepion Pharmaceuticals (NASDAQ:HEPA) completed enrollment of 60 non-alcoholic steatohepatitis (NASH) stage 3 (F3) subjects in the Phase 2 ALTITUDE-NASH clinical trial. The trial is being conducted in collaboration with...